Posttranslational processing of human and mouse urocortin 2: Characterization and bioactivity of gene products

Endocrinology

Volumn 154, Issue 4, 2013, Pages 1553-1564

  Vaughan, Joan M ^a,b   Donaldson, Cynthia J ^a   Fischer, Wolfgang H ^a   Perrin, Marilyn H ^a   Rivier, Jean E ^a   Sawchenko, Paul E ^b   Vale, Wylie W ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; GLYCOSYLATED PROTEIN; TISSUE EXTRACT; UROCORTIN II;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CONTROLLED STUDY; GENE PRODUCT; HUMAN; HUMAN CELL; MAMMAL CELL; MASS SPECTROMETRY; MELANOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PROCESSING;

AMINO ACID SEQUENCE; ANIMALS; CELL HYPOXIA; CELLS, CULTURED; CORTICOTROPIN-RELEASING HORMONE; GLYCOSYLATION; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; TRANSDUCTION, GENETIC; UROCORTINS;

EID: 84875858222     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-2011     Document Type: Article

References (40)

1. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A. 2001;98:2843-2848.
2. Hsu SY, Hsueh AJ. Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med. 2001;7:605-611.
3. Chen A, Blount A, Vaughan J, Brar BK, Vale W. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in CRFR1 and CRFR2-null mice and regulation by glucocorticoids. Endocrinology. 2004;145:2445-2457.
4. Imperatore A, Florio P, Torres P, et al. Urocortin 2 and urocortin 3 are expressed by the human placenta, deciduas, and fetal membranes. Am J Obstet Gynecol. 2006;195:288-295.
5. Karteris E, Hillhouse EW, Grammatopoulos D. Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility. Endocrinology. 2004;145:890-900.
6. Fekete EM, Zhao Y, Szucs A, et al. Systemic urocortin 2, but not urocortin 1 or stressin1-A, suppresses feeding via CRF2 receptors without malaise and stress. Br J Pharmacol. 2011;164:1959-1975.
7. Zorrilla EP, Reinhardt LE, Valdez GR, et al. Human urocortin II, a CRF2 agonist, and ovine CRF, a CRF1 agonist, differently alter feeding and motor activity. J Pharmacol Exp Ther. 2004;310:1027-1034.
8. Kuperman Y, Chen A. Urocortins: emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab. 2008;19:122-129.
9. Chen AM, Brar BK, Choi CS, et al. Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci U S A. 2006;103:16580-16585.
10. Emeto TI, Moxon JV, Rush C, Woodward L, Golledge J. Relevance of urocortins to cardiovascular disease. J Mol Cell Cardiol. 2011; 51:299-307.
11. Brar BK, Chen A, Perrin M, Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin- releasing factor (CRF) receptors 1 and 2β by the CRF/urocortin family of peptides. Endocrinology. 2004;145:1718-1729.
12. Kageyama K, Furukawa K, Miki I, Terui K, Motomura S, Suda T. Vasodilative effects of urocortin II via protein kinase A and a mitogen-activated protein kinase in rat thoracic aorta. J Cardiovasc Pharmacol. 2003;42:561-565.
13. Novembri R, Carrarelli P, Toti P, et al. Urocortin 2 and urocortin 3 in endometriosis: evidence for a possible role in inflammatory response. Mol Hum Reprod. 2011;17:587-593.
14. Chanalaris A, Lawrence KM, Stephanou A, et al. Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. J Mol Cell Cardiol. 2003;35:1295-1305.
15. Vaughan JM, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 1995;378:287-292.
16. Furutani Y, Morimoto Y, Shibahara S, et al. Cloning and sequence analysis ofcDNAfor ovine corticotropin-releasing factor precursor. Nature. 1983;301:537-540.
17. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci. 2002;23:71-77.
18. Buhler K, Plaisance I, Dieterle T, Brink M. The human urocortin 2 gene is regulated by hypoxia: identification of a hypoxia-responsive element in the 3′-flanking region. Biochem J. 2009;424:119-127.
19. Imperatore A, Rolfo A, Petraglia F, Challis JR, Caniggia I. Hypoxia and preeclampsia: increased expression of urocortin 2 and urocortin 3 Reprod Sci. 2010;17:833-843.
20. Semenov AG, Postnikov AB, Tamm NN, et al. Processing of probrain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. Clin Chem. 2009;55:489-498.
21. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006;1:241-245.
22. Vaughan JM, Rivier J, Corrigan AZ, et al. Detection and purification of inhibin using antisera generated against synthetic peptide fragments. Methods Enzymol. 1989;168:588-617.
23. Vale W, Vaughan J, Yamamoto G, et al. Assay of corticotropin releasing factor. Methods Enzymol. 1983;103:565-577.
24. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22:1393-1398.
25. Schjoldager KT, Vester-Christensen MB, Bennett EP, et al. O-glycosylation modulates proprotein convertase activation of angiopoietin-like protein 3: possible role of polypeptide GalNAc-transferase-2 in regulation of concentrations of plasma lipids. J Biol Chem. 2010;285:36293-36303.
26. Gram Schjoldager KT, Vester-Christensen MB, Goth CK, et al. A systematic study of site-specific GalNAc-type O-glycosylation modulating proprotein convertase processing. J Biol Chem. 2011;286: 40122-40132.
27. Bicknell AB. The tissue-specific processing of pro-opiomelanocortin. J Neuroendocrinol. 2008;20:692-699.
28. Dhanvantari S, Seidah NG, Brubaker PL. Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol. 1996;10:342-355.
29. Vaughan JM, Rivier J, Spiess J, et al. Isolation and characterization of hypothalamic growth hormone releasing factor from common carp, Cyprinum carpio. Neuroendocrinology. 1992;56:539-549.
30. Vaughan JM, Fischer WH, Hoeger C, Rivier J, Vale W. Characterization of melanin-concentrating hormone from rat hypothalamus. Endocrinology. 1989;125:1660-1665.
31. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods. 2011;8:785-786.
32. Isfort RJ, Wang F, Tscheiner M, et al. Modifications of the human urocortin 2 peptide that improve pharmacological properties. Peptides. 2006;27:1806-1813.
33. Loh YP, Gainer H. Evidence that glycosylation of pro-opiocortin and ACTH influences their proteolysis by trypsin and blood proteases. Mol Cell Endocrinol. 1980;20:35-44.
34. Eberlein GA, Eysselein VE, Davis MT, et al. Patterns of prohormone processing. Order revealed by a new procholecystokinin-derived peptide. J Biol Chem. 1992;267:1517-1521.
35. Funkelstein L, Hook V. The novel role of cathepsin L for neuropeptide production illustrated by research strategies in chemical biology with protease gene knockout and expression. Methods Mol Biol. 2011;768:107-125.
36. Pepels PP, Spaanderman ME, Hermus AR, Lotgering FK, Sweep CG. Placental urocortin-2 and-3: endocrine or paracrine functioning during healthy pregnancy? Placenta. 2010;31:475-481.
37. Hook V, Funkelstein L, Lu D, Bark S, Wegrzyn J, Hwang SR. Proteases for processing proneuropeptides into peptide neurotransmitters and hormones. Annu Rev Pharmacol Toxicol. 2008;48:393-423.
38. Rademaker MT, Cameron VA, Charles CJ, Richards AM. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation. 2005;112:3624-3632.
39. Rademaker MT, Charles CJ, Ellmers LJ, Lewis LK, Nicholls MG, Richards AM. Prolonged urocortin 2 administration in experimental heart failure: sustained hemodynamic, endocrine, and renal effects. Hypertension. 2011;57:1136-1144.
40. Takahashi K. Letter regarding article by Rademaker et al, "integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure". Circulation 2006;113:e710; author reply e710.